Dr. Tom Hawes
Tom is a Managing Director of the Blue Venture Fund.
He serves on the Board of Directors of Octave Bioscience, Perspectum, Upward Health, Owl Insights, and is a Board Observer of Onc.AI and Ultromics. Previously he served on the Board of InVivoLink (acquired by HCA), Nexidia (acquired by NICE), Phreesia (NYSE: PHR), Heartflow, Verata Health (acquired by Olive.Ai), and AbleTo (acquired by Optum), and a Board Observer of Thrive (NASDAQ: EXAS).
Before joining the Blue Venture Fund, Tom matched at Yale School of Medicine for residency and completed his first year of medical training at Greenwich Hospital. During his medical training, he worked on clinical studies at the ISK Institute for Orthopedics and Sports Medicine and on outcomes research at the National Cancer Institute and NYMC’s Cardiothoracic Surgery Department. Tom is on the National Advisory Board of the Desmoid Tumor Research Foundation.
Tom holds a BA from Brigham Young University, an M.D. from New York Medical College and an MBA from Harvard Business School. He is also a Kauffman Fellow.